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A 61-year-old obese female presented with hypothyroidism, insulin-independent diabetes
mellitus, and asymptomatic hepatomegaly. The diagnostic evaluation of hepatomegaly with
elevated transaminase is discussed. Liver biopsy findings are discussed. Plans for therapy are
presented and evaluated.
DR. JEFF BENDER (Resident in Medicine): The patient is a 61-year-old white female
who was admitted to the hospital in September 1981 for elective evaluation of three
problems for which shehad been followed over the last seven months. Those are dia-
betes mellitus, hepatomegaly, and hypothyroidism. The patient has a past medical
history significant for a transmural inferior wall myocardial infarct (MI) in 1975,
complicated by mild congestive heart failure, and a subsequent subendocardial MI
one month later. At that time, her onlymajor problem noted was obesity, which was
long-standing. Her weight in 1975 was 220 pounds. She was followed in the Primary
Care Center, and in 1976 she was first noted to be hyperglycemic. She was treated
initially with diet and attempted weight control, but this was unsuccessful and
her weight remained in the 215-220 pound range. Her plasma glucose concentra-
tions over the next two years rose to the 300 to 400 mg%o range, and the patient
was started on 15 units of NPH insulin per day. Subsequently this was increased
to 26 units of insulin per day, which brought her glucose level down to the 150 to
300 mg% range. By mid-1979 she had been lost to follow-up and consulted an out-
side physician. Her weight remained high, and when she returned to the Primary
Care Center in February 1981 her weight was still 215 pounds. During the interven-
ing period her insulin had been gradually increased. She was then being treated with
60 units of NPH in the morning and 30 units of NPH in the evening. Her fasting
bloodglucoses ranged from 208 to 450 mg%, and her urine was positive for glucose,
but negative for ketones. The initial attempt at management consisted of increasing
her insulin to doses as high as 70 units in the morning and 40 units at night. This
resulted in only a modest improvement, if any, with blood glucose levels persistently
300 to 350 mg%lo. She also had a five-pound weight gain to 220 pounds. Because of
her apparent resistance to insulin, an oral hypoglycemic agent was added in June
1981. With the addition of Diabinese her insulin requirements decreased. The addi-
tion of Diabinese seemed to dramatically improve her glucose tolerance with blood
glucoses falling to the low- to mid-200 mg% range. Subsequently her Diabinese was
increased to 500 mg per day, and NPH insulin was tapered from 70 to 40 units of
NPH insulin during the morning and from 40 to 10 units at night.
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Her second problem was hepatomegaly. She had no history of liver disease, no
history of alcohol abuse or excess, and, in the past, she had always had normal ab-
dominal exams and abdominal films which showed normal liver and spleen size.
When first seen in February 1981, she had a very firm liver, palpable a full six to
seven finger-breadths below the right costal margin, with a 20 cm span. A spleen tip
was not felt, although it was subsequently reported to be present by other observers.
Her liver function tests in February showed an SGOT of89 with all other liver func-
tion tests normal. Because the SGOT remained elevated two to three times above
normal, a further work-up was begun. Assays for hepatitis antigens and antibodies
were negative, a 5' nucleotidase level was markedly elevated at 29, but the alkaline
phosphatase level was normal, and antinuclear antibodies (ANA) were somewhat
elevated at 1:64. Serum iron and iron binding capacity and serum protein elec-
trophoresis were normal. Serum cholesterol, 235 mg%lo, and serum triglyceride, 232
mg%o, were slightly elevated. An ultrasound of the abdomen was normal except for
hepatomegaly, splenomegaly, and increased echogenicity diffusely present in the
liver. The liver-spleen scan showed hepatomegaly with inhomogeneous uptake and
a large shift ofcolloid to an enlarged spleen, compatible with hepatocellular disease.
During the course of this further work-up, her exam did not change. Her liver re-
mained the same in size, and her SGOT level was consistently between 60 and 100
units. SGPT values were similarly elevated. The liver service was consulted in Au-
gust 1981, six months after the abnormalities were first noted. They recommended
that a biopsy be performed, and this was the reason for the patient's admission in
September.
The third problem that had been noted in this patient was hypothyroidism. This
diagnosis was not suspected until Dr. Riely on the liver service saw the patient in
August and noted that she had some eyebrow loss and a hoarse voice. Thyroid func-
tion tests at the time showed an estimated free thyroxine (EFT) of0.1 with a TSH of
56. Thepatient was begun on Synthroid, but a very low dose was used because ofher
history of heart disease.
During the next six months the patient had multiple additional complaints, in-
cluding atypical chest pain, diffuse abdominal pain, multiple joint aches, depres-
sion, and dyspnea on exertion. She was a difficult historian, and there was an emo-
tional overlay to her complaints. Nevertheless, it was decided to admit her in
September to perform a liver biopsy, to further evaluate her atypical chest pain, and
to improve control of her diabetes.
At the time of admission she was a well-developed, well-nourished obese white
female. Her medications were insulin, Diabinese, digoxin, Lasix, and Synthroid (50
ytg/day). Her blood pressure was normal, as it always had been. Her skin showed
some decreased hair but was otherwise normal. The chest was clear. The cardiac
exam was normal with no murmurs or gallops. The abdominal exam showed that
she was obese and had mild right upper quadrant tenderness over her liver, which
was 16 to 18 cm in span and very firm to palpation without discrete nodules. A
spleen tip was felt by some observers. Her neurologic exam was normal with normal
reflexes. Her initial laboratory data included a normal BUN, normal electrolytes, a
hematocrit of 40 percent, a normal white cell count with normal differential,
platelets of 170,000/mm3, normal PT and PTT, and urinalysis which was normal ex-
cept for 2 + glucose by dipstick. Her chest X-ray was normal, and her cardiogram
was compatible with an old inferior wall MI.
PHYSICIAN: Did she have anti-thyroid globulins?
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DR. BENDER: Yes, her titer was 1:60.
DR. RALPH DEFRONZO (Associate Professor ofMedicine): This is an interesting lady,
and there are two major problems that I want to focus on today. One is the work-up
of an asymptomatic person with an elevation of the serum transaminases, and the
second is the approach to treatment of her diabetes and obesity. Table 1 is a rather
simplistic approach to the individual who is asymptomatic, and who has elevated
serum transaminases. This scheme is designed to look at the very selective patient
who has only an increase in the SGOT without elevation of other liver function tests
or other clinical signs or symptoms.
There are several things that one must rule out very quickly. Remember that
SGOT is present in many tissues. Therefore, first we must establish that the SGOT is
coming from liver. It is very common for a muscle disorder to cause an increase in
the SGOT, and, in particular, it is common to see an increased SGOT in joggers.
Obviously this lady who weighs 220 pounds is not a jogger, so it is unlikely that we
are going to be confused by that syndrome. However, in joggers the SGOT may be
persistently elevated. This etiology is easily excluded by obtaining a CPK level. Peo-
ple who have the "jogging syndrome" will have elevation in CPK along with the
TABLE 1
Elevated Transaminases in Asymptomatic Patient
A. Ascertain Hepatic Origin:
1. SGOT occurs in all body tissues, especially liver, heart, skeletal muscle; SGPT is present pri-
marily in liver and to a lesser extent in kidney and skeletal muscle.
2. Check 5' nucleotidiase and CPK.
3. History and physical examination.
4. Rule out "jogger's syndrome."
B. IfHepatic:
1. Unresolved hepatitis Parenteral drug abuse
Chronic persistent hepatitis
Chronic active hepatitis
Check HBsAg, anti-HBs, anti-HBc
2. Fatty liver Alcohol
Diabetes (GTT)
Obesity
Lipoprotein disorder (cholesterol, TG)
Inflammatory bowel disease (diarrhea)
3. Toxic hepatic injury Aspirin
Isoniazid
Tylenol
Methotrexate
4. Wilson's disease Ceruloplasmin
Kayser-Fleischer rings
5. Hemochromatosis Iron/total iron binding capacity
Ferritin
C. Further Work-Up: If no clue to pursue:
Liver-spleen scan
Abdominal ultrasound
Pancreas
Gallbladder
Liver biopsy
(Surprises: Granulomata, passive congestion, tumor)SIGAL AND DEFRONZO
SGOT. This patient's CPK was not elevated. Her SGPT was elevated as well. It also
is present in other tissues, including skeletal muscle and kidney, although it is a little
more specific for the liver. In addition, this patient had an elevated 5' nucleotidase,
and this led to the feeling that the SGOT was coming from the liver. The physical
finding of significant hepatomegaly was consistent with this impression.
In working up such an individual there are five disease categories that one has to
think about. It is possible that this lady could have an unresolved hepatitis, and the
most likely cause of this would be either hepatitis B or non-A, non-B hepatitis.
Hepatitis A does not progress to chronic persistent elevation of the SGOT, or at
least there has not been a case report described yet. One should look for the pres-
ence of hepatitis B surface antigen as well as antibodies to the surface antigen and
the core antigen. That was done in this lady, and they were all negative. It would
also be unlikely that this lady has chronic active hepatitis. Although this could be an
early presentation of chronic active hepatitis, one usually sees other abnormalities in
the liver function studies. Clearly, what she has could be consistent with chronic per-
sistent hepatitis, although the significant degree of hepatomegaly would argue
against this. With an elevated SGOT in the context of a significantly enlarged liver,
one has to pay serious attention to fatty liver disorders. The most common of these,
from a purely statistical basis, is going to be that associated with alcohol. This lady
and her family were questioned on numerous occasions about alcoholic intake, but
no history of alcoholism could be determined. Two other disorders which can be
associated with fatty liver and an increase in the transaminases are diabetes and
obesity. An elevation in the SGOT and hepatomegaly have also been reported with
certain lipoprotein disorders, even in the absence of diabetes and obesity. We know
that this patient had elevated serum triglyceride and cholesterol levels which would
place her in the Type IV category. Inflammatory bowel disease can also cause fatty
liver with an increase in the transaminases, and one should always ask about a
history of diarrhea. Obviously, there are certain drugs which can present with this
picture, and one must take a careful drug history. Aspirin and Tylenol are two of the
big offenders. Many people, particularly in this area, are on Isoniazid for pro-
phylaxis against tuberculosis, and the physician should also inquire about this
medication. The use of methotrexate has been described to cause a similar syn-
drome. Two other disorders which one must consider are Wilson's disease and
hemochromatosis. The work-up for these includes a careful eye examination and a
serum ceruloplasmin level and iron binding capacity. In this woman, they were all
normal.
Dr. Riely, could you please comment on the work-up I've outlined at this point?
When would you move to a liver biopsy? What would you expect to find in the
biopsy, and how might it alter your therapeutic approach to this particular lady?
DR. CAROLINE RIELY (Associate Professor ofMedicine and Pediatrics): For asymp-
tomatic elevations in SGOT alone, I would not move directly to a liver biopsy, but,
by the time I saw this patient, she had had abnormal liver function tests for six
months which would make it more appropriate. On the other hand, the most
remarkable thing about her was not the SGOT elevations, but the gigantic liver,
which should direct your work-up much more strongly than just the SGOT eleva-
tions. Looking at your list, I'd like to emphasize that the "jogger's syndrome" you
described is not rare. I have seen two patients referred to me in the last year for
elevated SGOT and SGPT who were joggers.
DR. DEFRONZO: That is an important point, since there is a tremendous jogging and
exercise fad now.
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DR. RIELY: Considering the rest ofyour list, inflammatory bowel disease is more like-
ly to present as a chronic active hepatitis or maybe a chronic persistent hepatitis,
rather than as fatty liver. Tylenol ingestion should not produce an SGOT elevation,
unless it is used in large amounts. Aspirin may elevate the SGOT. Wilson's disease I
consider in everybody, since it is totally treatable. However, the oldest patient that I
know of was 52 at the time he presented with asymptomatic esophageal varices. The
oldest patient we have seen here was a 42-year-old lady who came in with a picture
that resembled fulminant hepatitis. So, it is unusual to present with it in old age. The
other thing that often is forgotten is that anything which affects the body can af-
fect the liver. Certainly, thyroid disease, both hyper- and hypo-thyroidism, alone
can produce abnormal liver function tests. Cardiac disease is a common cause ofab-
normal liver function tests, particularly any condition which raises right-sided
pressures.
For someone who has an asymptomatic elevation of SGOT of six months' dura-
tion, in whom appropriate work-up has been pursued without identifying the cause,
I would recommend a liver biopsy to clarify the situation. In someone with
hepatomegaly and elevated liver function tests, I would biopsy sooner to determine
whether there is an infiltrate in the liver.
DR. DEFRONZO: So there are many things on this list that can cause an elevation of
the SGOT. Some ofthem will cause other abnormalities in liver function studies, but
if you put together the age, the associated medical conditions, and the markedly
enlarged liver you would agree that we're probably talking about those conditions
described under the category of fatty liver disease.
DR. RIELY: I think what that means is infiltration. The infiltration is less likely to be
inflammatory infiltration because that does not produce such big livers. It is more
likely to be due to something in the liver cells themselves, like fat or glycogen, or
something in other cells in the liver, as in Gaucher's disease, or something not in the
cells, but infiltrating the liver, such as amyloid.
DR. DEFRONZO: Would you have treated this patient's hypothyroidism to see if her
liver abnormalities corrected before doing a liver biopsy?
DR. RIELY: I had suggested that we make her euthyroid, and ifthe SGOT was still ab-
normal, that we proceed with a biopsy. However, her case was complicated by her
diabetes and heart disease, and we were reluctant to make her euthyroid abruptly.
DR. DEFRONZO: She did have a liver biopsy. Could we see the results of the biopsy?
DR. KEN BARWICK (Assistant Professor of Pathology): Let me give credit to Dr.
Gerald Klatskin who originally read and interpreted this biopsy. The histologic
changes of the biopsy are classic for alcoholic liver disease or for a few other pro-
cesses, as I will mention. On a low-power view ofthe needle biopsy, one sees broad,
regular bands of fibrous tissue that stain blue with the Masson-trichrome stain. At
low power one ascertains whether the lobular architecture is preserved. In this
specimen it is difficult to find the central and portal areas. This architecture has been
completely effaced and essentially destroyed. In addition to that, there are
regenerative nodules of hepatocytes with only minimal suggestions of normal
lobular architecture. The other finding that is quite striking at low power is the
massive degree of steatotosis (Fig. 1). So we have low-power evidence of a fibrosing
process which is almost certainly cirrhosis and that has totally destroyed the ar-
chitecture. One cannot find central vessels in looking through this biopsy, and one
can see that it has rather irregular fibrous scarring. The nodules are somewhat
similar in size, although that is a hazardous thing to determine on a biopsy of such
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_ E FIG. 1. Low power of
needle biopsy demonstrating
coarse fibrous bands which
divide the parenchyma into
nodules. The regenerative
g nodules contain many open
-' vacuoles of fat deposit.
small size. So we have at low power a type of cirrhosis that would fit into either
micronodular cirrhosis or Laennec's cirrhosis. At high power, using Masson-
trichrome stain, one can see the expanded portal areas in which there are entrapped
portal triad arteries and veins. It is important to ascertain whether there is an ongo-
ing injury being rendered upon the hepatocytes, and, if so, what is the degree of ac-
tivity. To determine whether or not there is ongoing injury, one studies the lining
plate ofhepatocytes around the triads, which should be a full layer; this is called the
limiting plate. It is rather difficult to define a limiting plate in cirrhosis as well-
formed as this, but by looking along the lining plates along the fibrous bands, there
is definitely an erosion of these cells. One could then try to determine whether the
hepatocytes in that area show either inflammation or hepatocellular injury. As we
move on to very high power we see that the cells adjacent to the fibrous tissue are
enlarged. This is often called ballooning, and the name "balloon hepatocyte" fits
very well. Within the cytoplasm, C-shaped or serpentine beaded coagulums are
present, representing Mallory bodies (Fig. 2). We can see these in a number of
hepatocytes present. When we look into the fibrous tissue to determine whether
there is ongoing inflammation, we find it is mild. The inflammatory cells which are
present are predominantly neutrophilic, as opposed to lymphocytes and plasma
cells, the latter being consistent with a post-viral injury pattern.- The neutrophils are
consistent with an alcoholic injury. There are scattered cells which are shrinking and
dying. These are called acidophilic bodies. They are not frequent in this specimen.
FIG. 2. Marked fatty
metamorphosis with one
hepatocyte containing a
Mallory body (arrow).
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One can thus determine that there is continuing insult and it is being rendered to the
hepatocytes, which is of a mild to moderate degree.
So, in summary, the diagnosis is that of cirrhosis which is a Laennec's or
micronodular type. There is very prominent fatty necrosis and an infiltrate which is
predominately neutrophilic. As I mentioned earlier, these are changes which are very
typical, indeed, classic, for alcoholic hepatitis. It has been appreciated recently that
the differential ofthis histologic pattern is broader than that, however, and includes
diabetes mellitus, obesity, non-alcoholic steatohepatitis, and post-ileojejunal
bypass. The appropriate choice from these possibilities must rest upon clinical
history.
DR. DEFRONZO: Are there any questions about the biopsy?
PHYSICIAN: Did you stain for glycogen?
DR. BARWICK: Yes, the specimen was stained for glycogen. There was someglycogen
present, but it was minimal.
DR. DEFRONZO: The findings in this patient point to the entity of non-alcoholic
steatonecrosis. One of the first articles to address this problem was published by
Leevy [1]. He reviewed 270 patients who had a histologic picture of cirrhosis and
fatty change and found that 77 percent ofthese people consumed very large amounts
of alcohol. On the other hand, he found that 23 percent of the population had this
exact histologic picture but with no history of alcohol consumption. In the non-
alcoholic fatty liver group there was a high prevalence ofdiabetes mellitus, including
both non-insulin-dependent and insulin-dependent patients. There was also a high
incidence of obesity. Not listed in his differential is the possible association with
lipoprotein disorders. He also reported a high incidence ofheart disease, and several
other series show that heart disease frequently occurs in association with non-
alcoholic fatty liver. Leevy postulated that there are four possible mechanisms via
which one could develop a fatty liver: (a) there could be an increase in free fatty acid
delivery to the liver cell; (b) there could be a decrease in fatty acid oxidation by the
hepatocytes; (c) there could be an increase in lipid synthesis by the hepatic cells; or
(d) there could be decreased packaging ofthelipid into lipoproteins by the liver cells,
leading to a reduction in transport to peripheral tissues. We now know that alcohol,
diabetes, and obesity affect each of these steps. Toxic drugs and alcohol have been
postulated to cause fatty changes in the liver by all four of these mechanisms.
However, it appears that the primary cause of this fat accumulation is a marked
decrease in fatty acid oxidation, due to decreased efficiency of the Kreb's cycle. In
diabetics there also appears to be an increased delivery of fat from peripheral stores
to the liver. There is also some evidence to suggest that there is a primary increase in
triglyceride synthesis within the liver, as well as a defect in the apoprotein necessary
to package the lipids into lipoproteins and transport them to the periphery. The
etiology of the fatty liver in obesity is less well-established. Some investigators have
postulated that there is an excessive amount ofglucose as well as fat in the diet which
is being directly deposited in the liver.
Two recent articles have addressed the problem ofnon-alcoholic fatty liver. One is
a series published by Ludwig et al. [2], from the Mayo Clinic. In 20 patients with
non-alcoholic steatohepatitis, they found a high incidence of obesity (90 percent)
and diabetes mellitus (25 percent), as well as a significant number of patients with
hyperlipoproteinemias, particularly Type IV (25 percent). Again, they also found
that a significant percentage of these people have cardiac disease (35 percent). Dr.
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this entity?
DR. RIELY: I do not think that they are causally related. All these patients are older,
in their 50s, usually, and cardiac disease is very common.
DR. DEFRONZO: It would appear that cardiac disease occurs quite frequently, but no
one really knows whether it has any etiologic significance. Dr. Ludwig pointed out
in his article that patients with non-alcoholic fatty liver frequently develop polymor-
phonuclear infiltration, necrosis of liver cells, Mallory bodies, alcoholic hyaline,
and fibrosis that would eventually lead to cirrhosis. In a subsequent paper by Adler
and Schaffner [3] similar findings were observed. They also emphasized the frequent
occurrence of lipoprotein disorders unassociated with diabetes and obesity. Most
recently Denis Miller and Gerry Klatskin have looked at a similar group of27 people
here at Yale [4]. Again, the histological changes they found were indistinguishable
from those observed in alcoholic cirrhosis. They also reported that some ofthese pa-
tients can develop advanced signs of liver disease in addition to hepatomegaly. A
large number had splenomegaly (nine), or developed ascites (nine), jaundice (seven),
encephalopathy (four), and varices (seven). So this is not a benign disorder, even
though it is not associated with alcohol.
Drenick et al. [5] studied obese people with non-alcoholic fatty liver. They treated
these people either by a total fast, by a hypocaloric weight-reducing diet, or by in-
testinal bypass. Pre-treatment biopsies demonstrated non-alcoholic hepatic fatty in-
filtration and cirrhosis. On follow-up, the group treated by fasting and the group
treated by diet had almost complete resolution of their liver disease. In contrast,
those who were treated with intestinal bypass got much worse. It is now well known
that intestinal bypass is associated with its own type of cirrhosis and fatty infiltra-
tion. In summary, this article suggests that weight reduction can be an effective
means of treating the liver disease. There also is some anecdotal evidence that tight
diabetic control will alleviate the liver disease in diabetic subjects. How should one
approach the treatment of the metabolic derangements that occur in diabetic and
obese people? In order to begin treating such individuals, one must have an under-
standing of the mechanisms underlying the glucose intolerance in such patients.
I'd like to review some studies that we've carried out to define the mechanism of
glucose intolerance in obesity and in diabetes mellitus. We have employed the insulin
clamp technique to quantitate tissue sensitivity to insulin. Briefly, the patient's
plasma insulin concentration is raised by 100 u/ml and a variable glucose infusion is
simultaneously given to maintain the plasma glucose concentration at the basal
level. Under these steady-state conditions of glycemia, the rate at which the glucose
is infused must exactly be equal to the rate at which all the tissues are taking up the
glucose. Therefore, the total amount of glucose which is infused during the study
provides a measure ofthe body's sensitivity to the insulin that was given. In obese in-
dividuals we have shown that the tissues of the body are severely resistant to the ac-
tion of insulin. The total amount of glucose metabolized is reduced by 50 percent
compared to normal individuals studied with the same dose ofinsulin. Thus, one of
the major metabolic disturbances in obesity is an inability to respond normally to
the insulin that one's own body makes or to the insulin that is infused exogenously.
What about non-insulin-dependent diabetic subjects? It turns out that Type II dia-
betes is also characterized by insulin resistance, which may be even more severe than
in the non-diabetic obese individual. The patient under discussion here was treated
with insulin, and one could argue that she is, therefore, an insulin-dependent
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diabetic. However, it is likely that she still has residual, albeit diminished, insulin
secretion and would be classified as a Type II, or non-insulin-dependent, diabetic
(NIDD). Recently, we have also demonstrated that insulin-dependent diabetics, in
the absence of circulating antibodies, are markedly insulin-resistant. Therefore,
whether we say our patient is insulin-dependent or insulin-independent is not going
to make a difference with respect to the presence or absence of insulin resistance. It
should be emphasized that the combination ofdiabetes and obesity will make the pa-
tient particularly resistant to the action of insulin. When thinking about treatment
of such an individual, one would like to institute measures that will specifically im-
prove the body's response to insulin. There are three things that can do this. The first
is physical training. In this particular woman, we can encourage that, but it is
unlikely to be very successful. The second is use of oral sulfonylurea agents. One
could argue that in a diabetic who is difficult to control, either insulin-dependent or
insulin-independent, ifthe major problem is one ofinsulin resistance, and ifthe oral
agents have as their major mechanism of action an increase in tissue sensitivity to in-
sulin, then one should see an improvement in the patient's glucose tolerance. We
have looked at this using an oral sulfonylurea agent in a group of non-insulin-
dependent diabetics, who had fasting glucose levels of about 200 mg%o. After being
on the oral agent for three days, the fasting glucose concentration decreased to 170
mgVo. After three months of treatments, the plasma glucose declined to 140 mg%fo.
This decrease in fasting glucose was found to be entirely due to a decrease in hepatic
glucose production without any change in the basal insulin level. Thus, the oral
agents seem to inhibit the overproduction of glucose by the liver that occurs under
post-absorptive conditions. Insulin clamp experiments in those subjects show a
marked improvement in insulin sensitivity, as well, after three days and three
months of treatment. Therefore, oral agents appear to have a major effect of en-
hancing tissue sensitivity to insulin in addition to their ability to augment secretion.
In fact, on a long-term basis, it is difficult to show that oral agents enhance insulin
secretion. Dr. Bender, when you placed this woman on Diabinese, you noted that
there was a marked reduction in her insulin requirements, and her diabetes came
under better control. Was there any change in her weight or diet or other factors that
could have been responsible for the improvement in glucose control?
DR. BENDER: Her weight was stable at 215 pounds, and I don't believe she had any
changes in her diet. She had been counseled for years and had not changed her diet.
DR. DEFRONZO: We are presently investigating the effects of oral agents in insulin-
dependent diabetics who are relatively insulin-resistant and require large amounts of
insulin. We hope that improved tissue responsiveness to insulin will improve glucose
control and decrease the daily insulin requirement, since there is recent evidence to
suggest that such high insulin doses may be atherogenic. This is the third case we
have seen in which insulin requirements have dropped in half, and patients have
come under better control. It is possible, therefore, that the oral agents can be a
useful means of therapy. What about weight reduction, per se? If one takes a nor-
mal person who is overweight, but not diabetic, and reduces that person's weight,
one sees a significant improvement in glucose tolerance. It has also been shown that
in the obese individual there is marked hyperinsulinemia, with plasma levels often in
excess of 150 u/ml, following an oral glucose load. After weight reduction, glucose
tolerance improves despite a decrease in the plasma insulin response. This can only
be explained by increased tissue sensitivity to insulin. The obese diabetic with fasting
glucose levels above 200 mg/dl is very different, however. Such a person has a flat
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insulin response to an oral glucose load. Four large studies have shown that if this
person is weight-reduced, there is improved tolerance of glucose, enhanced tissue
sensitivity to insulin, and improved insulin secretion. It is now clear that even
moderate obesity is associated with insulin resistance. The beta cell tries to overcome
this resistance by secreting more insulin, but eventually the beta cell exhausts itself,
and an insulinopenic state results. If one can reduce the insulin resistance, however,
the beta cell may recover its capacity to secrete insulin. There are dramatic cases of
insulin-dependent diabetics who, after weight reduction, lost their requirement for
insulin. Diabetes researchers now know that weight reduction in an obese diabetic
will not only decrease the insulin resistance, giving better glucose tolerance, but will
allow the beta cells to recover function also. Normalizing body weight, then, is an
important goal to strive for. I am going to ask Bob Sherwin to comment on the type
of diet that he thinks would be beneficial for this patient.
This is not an easy problem in this lady, since she has liver disease. She will need a
diet that will not make her liver disease worse, yet she needs to lose weight. If you
were treating this woman, what type ofdiet would you recommend, and what would
be the theoretical basis for this recommendation?
DR. ROBERT SHERWIN (Associate Professor ofMedicine): I have a couple of com-
ments before we discuss specific dietary recommendations. Of the available oral
agents, I would not have chosen Diabinese to treat this patient, since it is the one
most likely to cause hepatotoxicity. Usually it requires doses above 750 mg to do so,
but in someone who has underlying liver disease I would be more cautious. I would
have chosen another agent, even though Diabinese is potentially the most effective
antidiabetic agent available on the market today. The other issue concerns the use of
insulin in a patient with severe obesity. I personally would not have used insulin in
this lady. Often, such patients show an initial response, but later they do not do very
well. They often gain additional weight and become more insulin-resistant and
glucose-intolerant. I would venture to guess that discontinuing her insulin, by itself,
would have produced very little change in her condition.
DR. BENDER: She is now off insulin, and her glucose level is about 200 mg%lo.
DR. SHERWIN: Chances are that even before you started her oral agent, you could
have taken her off insulin, and nothing would have changed. That has been my
clinical experience.
The best way to treat this lady is by weight reduction and not by oral agents.
However, it is usually easier and more effective in general terms to give oral agents
because patients will take them. This patient has several strikes against her when she
tries to lose weight. One is that she is a woman, and women do not lose weight as
well as men for some reason. Two, she was markedly obese, and the fatter the per-
son, the less likely they are to lose weight. Third, she had long-standing obesity,
and the longer the history of obesity, the worse the outcome. If a patient becomes
obese beforepuberty, the likelihood ofsuccess is extremely small. The best factor, in
terms of outcome, is that she has some underlying disease, diabetes mellitus, and
that can provide a motivating focus for the patient. But unless one has adequate
motivation and an adequate follow-up system, the dietary measures that we
prescribe are often not effective.
I would be careful about the use of total fasting to help this woman lose weight.
Although that would be effective in mobilizing some of her fat stores, the risks are
considerable, and the potential benefits are not much greater with a hypocaloric
diet. If the key thing you want to do is to have the patient lose weight, a moderate
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caloric restriction diet will achieve that. It might be a little slower than total fasting,
but the end result will be the same, and the patient is likely to maintain the weight
loss. Our experience with total fasting patients has not been rewarding. After leaving
the hospital they usually regain what weight they have lost. Therefore, I would
probably put this lady on a diet containing 800-1,000 calories that supplies an ade-
quate amount of protein, a little over 1 gram/kg of body weight. Since this woman's
ideal body weight is about 50 kg I would include about 70 g of protein, and I would
also include a small amount of essential fatty acids. The rest of the calories should
be supplied as fat or as carbohydrates. The proportions of these do not matter much
in the long run. Unfortunately, the medical profession does not ordinarily offer
much more to a patient other than diet. There often is not adequate follow-up or
adequate encouragement for the patient in the long term to really make it work. The
best thing to do would be to refer her to a place where there are people who are
following patients on a weekly basis, such as a self-help referral group. Long-term
behavior modification, once weight reduction is achieved, is a reasonable approach.
DR. DEFRONZO: Dr. Bender, what has happened since the biopsy?
DR. BENDER: Dr. Sherwin mentioned that the liver biopsy might motivate her. In-
deed, when her biopsy came back as severe cirrhosis, that became a strong
motivating factor, and she now has lost 30 pounds. Her SGOT is now normal, and
she is offinsulin. I do not know how well that correlates with her liver disease, as she
still has a very large liver.
DR. DEFRONZO: I'd like to point out that in the paper by Drenick et al. [51 which
showed return of normal liver function in obese people who lost weight, the weight
reduction achieved was greater than 100 pounds.
In summary, there are two points to be emphasized. First, non-alcoholic hepatitis
can be as dangerous as alcoholic hepatitis, but correction of the underlying meta-
bolic disorder in obesity or diabetes may improve liver function. Second, if one can
reduce insulin resistance by some of the methods that we've talked about, glucose
tolerance will improve, and the beta cells may recover significant insulin secretory
function.
DR. ALAN KLIGER (Associate Professor of Medicine): You have a patient with
hypothyroidism and anti-thyroid antibodies, along with diabetes mellitus and anti-
nuclear antibodies. Is there a way to tie all of these together?
DR. DEFRONZO: This lady could fall into the Schmidt's syndrome of multiglandular
failure. I'll ask Bob Lang to comment on this. How exhaustively would you work up
such an individual? Would you test for adrenal function or look for pernicious
anemia?
DR. ROBERT LANG (Associate Professor ofMedicine): Hypothyroidism and diabetes
are, by far, the two most common endocrine gland failure disorders that we see in
the syndrome of multiglandular failure, as well as in the general population. We
now know that the syndrome originally described by Schmidt [6], which was lym-
phocytic thyroiditis and non-tuberculous Addison's disease, is due to an autoim-
mune disorder. Most clinicians now include diabetes mellitus as part of Schmidt's
syndrome, and, unlike this patient, most will have insulin-dependent diabetes
mellitus. I personally do not work up every gland in every patient with Schmidt's
syndrome, but I keep the thought in the front of my mind that it is possible that
there may be failure of other glands. One needs a very high index of suspicion to
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undertake a large work-up, and the physician should educate these patients to return
if symptoms from other glandular failure occur.
DR. DEFRONZO: Although these people may develop hypoparathyroidism, pernicious
anemia, and a variety of other "autoimmune disorders," as Dr. Lang has pointed
out, you don't need to institute an exhaustive work-up unless the history or physical
examination points to some specific organ system dysfunction.
DR. SHERWIN: This syndrome of multiglandular failure is extremely rare. Further,
95-99 percent of them have Type I diabetes, which is a different entity than the
problem this patient has. The other thing to remember is that insulin seems to
enhance the conversion ofT4 to T3. Patients with Type I diabetes, even without an-
tibodies, tend to have relatively low T3 levels.
DR. BENDER: The patient had an elevated TSH.
DR. SHERWIN: Yes, she was clearly hypothyroid, but one should probably not invoke
polyglandular failure in a Type II diabetic.
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